Factors Associated With MOG‐IgG Serostatus Change
ABSTRACT Neurologists often re‐test MOG‐IgG, but the frequency and factors associated with serostatus change are unknown. We examined this issue in a clinical cohort of patients serially tested for MOG‐IgG at Cleveland Clinic between 2017 and 2025. Kaplan–Meier curves estimated seroconversion/seroreversion‐free probability. Of 272 with serial testing, 16 seroreverted (to negative), 4 seroconverted (to positive). At 1 year, seroreversion‐free probability was 85% (95% CI: 76%, 96%) and seroconversion‐free probability was 98% (95% CI: 95%, 100%). Seroreversion occurred in 16 of 59 (27%), of whom 11 had titers < 1:100; none had further relapses. Seroconversion was uncommon (< 2%) and occurred in patients with steroid treatment at initial testing.
Authors
- Amy C. Kunchok (ORCID: https://orcid.org/0000-0002-8387-6491)
- Jeffrey Allen Cohen (ORCID: https://orcid.org/0000-0001-9245-9772)
- Mengke Du (ORCID: https://orcid.org/0009-0004-6283-1990)
- Katherine Havard‐Coiro (ORCID: https://orcid.org/0009-0004-4959-0328)
Institutions
- Cleveland Clinic (US)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1002/acn3.70551
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00